Familial prostatic cancer risk and low testosterone

Area of Science:

• Urology
• Genetics
• Endocrinology

Background:

• Prostate cancer is a significant health concern with potential familial aggregation.
• The role of sex steroids, particularly androgens, in prostate cancer development is under investigation.
• Understanding familial influences can elucidate prostate cancer etiology and inform risk assessment.

Purpose of the Study:

• To determine if familial factors influence prostate cancer incidence.
• To investigate the association between familial relationships and plasma sex steroid levels.
• To explore the potential genetic and hormonal underpinnings of prostate cancer risk.

Main Methods:

• Comparative analysis of prostate cancer incidence in brothers of cases versus controls (brothers-in-law, general population).
• Intraclass correlation analysis of plasma testosterone, free testosterone, dihydrotestosterone, and testosterone/dihydrotestosterone ratios in familial cohorts.
• Comparison of plasma androgen levels between prostate cancer probands/relatives and age-matched controls.

Main Results:

• Brothers of prostate cancer cases exhibited a 4-fold higher relative risk compared to controls.
• Significant intraclass correlations for testosterone and free testosterone were found in cases and their brothers.
• Significant correlations for dihydrotestosterone and testosterone/dihydrotestosterone ratio were observed between sons and fathers.
• Prostate cancer probands and their relatives showed significantly lower plasma testosterone levels than controls.
• Plasma androgen levels were found to be clustered in the lower normal range within families affected by prostate cancer.

Conclusions:

• Familial factors, potentially genetic, are potent risk factors for prostate cancer development.
• Familial aggregation influences plasma androgen levels, suggesting a shared biological basis.
• Lower plasma androgen levels may be associated with increased prostate cancer risk within families.